SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.
about
The role of FLT3 in haematopoietic malignanciesDownstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implicationsAnti-angiogenic therapies for metastatic colorectal cancer: current and future perspectivesChloroquine and hydroxychloroquine for cancer therapyIndividualising treatment choices in a crowded treatment algorithmInhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemiaPrimary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumorThe outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.Sunitinib in the treatment of metastatic renal cell carcinomaPatient-derived tumour xenografts for breast cancer drug discoverySunitinib in solid tumorsAdvanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendationsMutant FLT3 signaling contributes to a block in myeloid differentiationHuman iPSC-derived endothelial cell sprouting assay in synthetic hydrogel arraysThe 4q12 amplicon in malignant peripheral nerve sheath tumors: consequences on gene expression and implications for sunitinib treatment(3)D [corrected] quantification of tumor vasculature in lymphoma xenografts in NOD/SCID mice allows to detect differences among vascular-targeted therapiesAn ex vivo model for anti-angiogenic drug testing on intact microvascular networksProdrug AST-003 Improves the Therapeutic Index of the Multi-Targeted Tyrosine Kinase Inhibitor SunitinibRegistered report: Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukemiaLymphangiogenesis is required for pancreatic islet inflammation and diabetesInteraction of green tea polyphenol epigallocatechin-3-gallate with sunitinib: potential risk of diminished sunitinib bioavailabilityEnhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for CancerSystematic identification of genomic markers of drug sensitivity in cancer cellsSunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program.Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.Sunitinib malate for the treatment of solid tumours: a review of current clinical data.Cell-based selection of internalizing fully human antagonistic antibodies directed against FLT3 for suppression of leukemia cell growth.Systemic therapy options for unresectable and metastatic chordomas.Precancerous stem cells can serve as tumor vasculogenic progenitors.Phase II study of sunitinib as second-line treatment for advanced gastric cancer.Sunitinib in metastatic renal cell carcinoma patients with brain metastases.Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study.A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancerFirst-line sunitinib plus FOLFIRI in Japanese patients with unresectable/metastatic colorectal cancer: a phase II study.A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors.Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study.Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer.Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study.Sunitinib in metastatic renal cell carcinoma: an ethnic Asian subpopulation analysis for safety and efficacy.
P2860
Q24319174-48451AA9-F258-44E4-9360-B697FE7350C8Q24617091-CDECAD8A-1565-4AF1-A0F9-E7DE4C1CE4DEQ26826817-E589FAE7-62EC-436D-804B-D5D8E77E54C5Q26827797-6B3C7AFF-9931-4E14-8E54-47E86BBAF26DQ27023669-BF438988-E31F-49DD-BA8C-7B8CE204C708Q27674674-3305680C-BA85-414A-BF35-7A09458620E3Q27851455-E483A84D-5CCC-4106-8B07-50ADA7F4F560Q27851744-94E37338-0C0F-47EF-BD2F-E3FE14BE5985Q27852520-ABD8B274-7E61-440F-AFBE-5F5CB0DCDCDBQ28072057-C3BCF210-126B-436F-B55C-FB143B2D9635Q28080046-88BEB0B5-3730-4F48-9161-C1678DEACBAAQ28245467-5F7A8822-4D32-492A-9ADE-018793868DDFQ28247449-9ED0EAAC-14A1-42D1-87C3-79307A4C9C0FQ28279890-31FB6EDB-BF45-4E8D-9ADE-95216A04B98BQ28397986-A65E61F8-5EC3-4EF8-9499-3647CB6B87E7Q28474942-6D0DBC15-1218-4D8F-BCA1-126E75AD6769Q28488869-311314C4-284A-4795-BA94-FBB55CF575D8Q28543862-D17FD878-0FDC-4C91-8775-32A024234B9EQ28550556-A1F49419-6561-473B-A643-FD70DFB6D60FQ28608331-7E36F1B2-203E-4000-8512-BACE58110F9EQ28742322-84620861-38C6-4FF0-A6C3-388E5E7A7ECBQ29012696-0D231CA3-0E5B-4959-B86E-E8398753A1E1Q29147555-DB8F0EC7-B58D-4695-9AE6-8103E39C9078Q29547695-E28FABE3-A457-4595-8908-FCA4AD8DACD1Q30313895-5B4424D1-0C5C-4DDB-9E20-0284C118B494Q30422736-91D4A643-9754-451D-9BFA-33A59EB90976Q31037756-629A624C-42E9-4A94-AF6D-5ACE0F1880B8Q33216322-4EC9AC0B-93AE-414F-BCFD-6190E32ACDE2Q33274146-25A2CC05-56CA-45F4-B20A-52F5FB42553DQ33320547-6839D59E-E36F-4603-9354-E09A6D6E6355Q33389519-DDD8FAA3-8550-4E34-8BD3-6BA3B1976467Q33391978-832A6313-A296-43C2-85E6-01CD9898EF63Q33395853-A40B0E78-05DC-4FAB-84EB-A40B263F8C34Q33397590-D649FCF7-EDA2-4251-A33E-A2A777ABD153Q33400952-B370D38D-3E75-4997-9054-7222107DAA53Q33401396-D9F0DDE3-CFE5-4A0C-AB37-6DE4111CD967Q33406542-80C6E85C-AD65-4819-ADBD-0A511B5F841BQ33407676-EB118EF3-F1FE-43DE-B68D-E87D032A7644Q33409913-D5AA9405-023B-4B74-9131-9757C523BD42Q33413566-3A2540B8-47FF-4BA7-B729-9649FBEC5AC3
P2860
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
SU11248 is a novel FLT3 tyrosi ...... activity in vitro and in vivo.
@en
SU11248 is a novel FLT3 tyrosi ...... activity in vitro and in vivo.
@nl
type
label
SU11248 is a novel FLT3 tyrosi ...... activity in vitro and in vivo.
@en
SU11248 is a novel FLT3 tyrosi ...... activity in vitro and in vivo.
@nl
prefLabel
SU11248 is a novel FLT3 tyrosi ...... activity in vitro and in vivo.
@en
SU11248 is a novel FLT3 tyrosi ...... activity in vitro and in vivo.
@nl
P2093
P1433
P1476
SU11248 is a novel FLT3 tyrosi ...... activity in vitro and in vivo.
@en
P2093
Anne-Marie O'Farrell
Beverly D Smolich
Helene A Yuen
Julie M Cherrington
Kevin W H Yee
Lesley J Murray
Leslie B Lee
Lily M Wong
Sharianne G Louie
P304
P356
10.1182/BLOOD-2002-07-2307
P407
P577
2003-01-16T00:00:00Z